Substance / Medication

Butenafine

Overview

Active Ingredient
butenafine
RxNorm CUI
47461

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Use of an in vitro human skin permeation assay to assess bioequivalence of two topical cream formulations containing butenafine hydrochloride (1%, w/w).
Mitra Amitava, Kim Nanhye, Spark Darren et al. · Regul Toxicol Pharmacol · 2016
PMID: 27816671Observational
[Activity of butenafine against ocular pathogenic filamentous fungi in vitro].
Xu Yan, Pang Guang-ren, Zhao Dong-qing et al. · Zhonghua Yan Ke Za Zhi · 2010
PMID: 20388321Observational
Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial.
Singal Archana, Pandhi Deepika, Agrawal Subhav et al. · J Dermatolog Treat · 2005
PMID: 16428155Observational
Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria.
Kokjohn Katrina, Bradley Mary, Griffiths Brian et al. · Int J Dermatol · 2003
PMID: 12895182Observational
Extended Antimicrobial Profile of Chromone-Butenafine Hybrids.
Bonvicini Francesca, Menegaldo Lisa, Orioli Rebecca et al. · Molecules · 2025
PMID: 40733240OtherFull text (PMC)
Novel nanomicelle butenafine formulation for ocular drug delivery against fungal keratitis: In Vitro and In Vivo study.
Lu Ping, Liang Zhen, Zhang Zhen et al. · Eur J Pharm Sci · 2024
PMID: 37918544Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Butenafine (substance)
SNOMED CT
373449007
UMLS CUI
C0107497
RxNorm CUI
47461

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.